This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (86)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Glaucoma  • Ophthalmological Disorders, Other  • Alert me on articles by topic

Design and Baseline Description of the Participants

Mae O. Gordon, PhD; Michael A. Kass, MD; for the Ocular Hypertension Treatment Study Group

Arch Ophthalmol. 1999;117:573-583.

Background  The Ocular Hypertension Treatment Study (OHTS) seeks to evaluate the safety and efficacy of topical ocular hypotensive medication in preventing or delaying the onset of visual field loss and/or optic nerve damage in subjects with ocular hypertension at moderate risk for developing primary open angle glaucoma.

Objective  To describe the study protocol, the questions to be answered, and the baseline characteristics of the subjects.

Design  Multicenter randomized clinical trial with 2 groups: topical ocular hypotensive medication and close observation.

Setting  Subjects were enrolled and evaluated at 22 participating clinical centers. Visual fields and stereoscopic optic disc photographs were read in masked fashion.

Methods  We determined eligibility from a comprehensive eye examination, medical and ocular history, visual field testing, and stereoscopic optic disc photography.

Results  We describe the baseline characteristics of 1637 subjects randomized between February 28, 1994, and October 31, 1996. The mean age was 55 years; 56.9% of the subjects were women; and 25% were African American. The baseline intraocular pressure was 24.9±2.7 mm Hg (mean±SD). Systemic diseases and conditions reported by subjects included previous use of medication for ocular hypertension, 37%; systemic hypertension, 38%; cardiovascular disease, 6%; diabetes mellitus, 12%; and family history of glaucoma, 44%. The mean horizontal cup-disc ratio by contour estimated from stereophotography was 0.36±0.18. Qualifying Humphrey 30-2 visual fields had to be normal and reliable for entry into the study. Health-related quality of life (36-item short form health survey) scores in the OHTS sample were better than the age- and sex-matched population norms. African American subjects had larger baseline cup-disc ratios and higher reported rates of elevated blood pressure and diabetes than the rest of the subjects.

Conclusions  The intraocular pressure among enrolled subjects was sufficiently high to provide an adequate test of the potential benefit of ocular hypotensive medication in preventing or delaying glaucomatous damage. The large number of African American subjects enrolled should provide a good estimate of the African American response to topical medication.

From the Department of Ophthalmology and Visual Sciences, Washington University, St Louis, Mo. See the box on pages 581-582 for a list of the participating clinics, committees, and resource centers in the Ocular Hypertension Treatment Study.

RELATED LETTER

Diabetes and Glaucoma
Michael A. Kass, Mae O. Gordon, and for the Ocular Hypertension Treatment Study Group
Arch Ophthalmol. 2008;126(5):746-747.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 1999;117(5):707-708.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diabetes and Glaucoma
Kass et al.
Arch Ophthalmol 2008;126:746-747.
FULL TEXT  

Practical recommendations for measuring rates of visual field change in glaucoma
Chauhan et al.
Br. J. Ophthalmol. 2008;92:569-573.
ABSTRACT | FULL TEXT  

Glaucoma detection with matrix and standard achromatic perimetry
Burgansky-Eliash et al.
Br. J. Ophthalmol. 2007;91:933-938.
ABSTRACT | FULL TEXT  

American Chinese Glaucoma Imaging Study: A Comparison of the Optic Disc and Retinal Nerve Fiber Layer in Detecting Glaucomatous Damage
Leung et al.
IOVS 2007;48:2644-2652.
ABSTRACT | FULL TEXT  

Some dissociating factors in the analysis of structural and functional progressive damage in open-angle glaucoma
Hudson et al.
Br. J. Ophthalmol. 2007;91:624-628.
ABSTRACT | FULL TEXT  

Comparison of Initial Intraocular Pressure Response With Topical beta-Adrenergic Antagonists and Prostaglandin Analogues in African American and White Individuals in the Ocular Hypertension Treatment Study
Mansberger et al.
Arch Ophthalmol 2007;125:454-459.
ABSTRACT | FULL TEXT  

Peripapillary fundus perimetry in eyes with glaucoma
Convento et al.
Br. J. Ophthalmol. 2006;90:1398-1403.
ABSTRACT | FULL TEXT  

Differences in Visual Function and Optic Nerve Structure Between Healthy Eyes of Blacks and Whites
Racette et al.
Arch Ophthalmol 2005;123:1547-1553.
ABSTRACT | FULL TEXT  

Validation of a Predictive Model to Estimate the Risk of Conversion From Ocular Hypertension to Glaucoma
Medeiros et al.
Arch Ophthalmol 2005;123:1351-1360.
ABSTRACT | FULL TEXT  

Baseline Topographic Optic Disc Measurements Are Associated With the Development of Primary Open-Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study
Zangwill et al.
Arch Ophthalmol 2005;123:1188-1197.
ABSTRACT | FULL TEXT  

The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals
Higginbotham et al.
Arch Ophthalmol 2004;122:813-820.
ABSTRACT | FULL TEXT  

The Relationship between Standard Automated Perimetry and GDx VCC Measurements
Reus and Lemij
IOVS 2004;45:840-845.
ABSTRACT | FULL TEXT  

Racial Differences in Optic Disc Topography: Baseline Results From the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study
Zangwill et al.
Arch Ophthalmol 2004;122:22-28.
ABSTRACT | FULL TEXT  

Comparison of Different Methods for Detecting Glaucomatous Visual Field Progression
Vesti et al.
IOVS 2003;44:3873-3879.
ABSTRACT | FULL TEXT  

Classification of Visual Field Abnormalities in the Ocular Hypertension Treatment Study
Keltner et al.
Arch Ophthalmol 2003;121:643-650.
ABSTRACT | FULL TEXT  

Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
Heijl et al.
Arch Ophthalmol 2002;120:1268-1279.
ABSTRACT | FULL TEXT  

Comparison of Glaucomatous Visual Field Defects Using Standard Full Threshold and Swedish Interactive Threshold Algorithms
Budenz et al.
Arch Ophthalmol 2002;120:1136-1141.
ABSTRACT | FULL TEXT  

Using Machine Learning Classifiers to Identify Glaucomatous Change Earlier in Standard Visual Fields
Sample et al.
IOVS 2002;43:2660-2665.
ABSTRACT | FULL TEXT  

A few remarks about glaucoma
Wegner
Br. J. Ophthalmol. 2002;86:836-837.
FULL TEXT  

The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma
Kass et al.
Arch Ophthalmol 2002;120:701-713.
ABSTRACT | FULL TEXT  

The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma
Gordon et al.
Arch Ophthalmol 2002;120:714-720.
ABSTRACT | FULL TEXT  

Correlation of the Binocular Visual Field with Patient Assessment of Vision
Jampel et al.
IOVS 2002;43:1059-1067.
ABSTRACT | FULL TEXT  

Increased Corneal Thickness in Patients With Ocular Hypertension
Herman et al.
Arch Ophthalmol 2001;119:334-336.
ABSTRACT | FULL TEXT  

Confirmation of Visual Field Abnormalities in the Ocular Hypertension Treatment Study
Keltner et al.
Arch Ophthalmol 2000;118:1187-1194.
ABSTRACT | FULL TEXT  

Causes of Visual Impairment and Common Eye Problems in Northwest American Indians and Alaska Natives
Mansberger et al.
Am. J. Public Health 2005;95:881-886.
ABSTRACT | FULL TEXT